Cytokinetics Files Shelf Registration Statement

South San Francisco, CA - June 14, 2005

Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it has filed a shelf registration statement with the Securities and Exchange Commission (SEC). This registration statement, upon being declared effective by the SEC, will allow Cytokinetics to sell from time to time up to $100 million, in aggregate, of its common stock, preferred stock and warrants. These securities may be offered from time to time, separately or together, in amounts, at prices and on terms set forth in the prospectus contained in the registration statement, and in one or more supplements to the prospectus. All of the securities sold in the offering will be sold by Cytokinetics, and proceeds from such sales will be used for the purposes described in the prospectus and in any prospectus supplement filed at the time of an offering.

The registration statement relating to the securities has been filed with the SEC but has not yet become effective. The securities may not be sold, nor may offers to buy the securities be accepted prior to the time the shelf registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Cytokinetics

Cytokinetics is a leading biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that specifically target the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Cytokinetics’ focus on the cytoskeleton enables it to develop novel and potentially safer and more effective classes of drugs directed at treatments for cancer, cardiovascular disease and other diseases.